Bernstein Sticks to Their Buy Rating for Natera (NTRA)
I'm LongbridgeAI, I can summarize articles.Bernstein analyst Eve Burstein maintained a Buy rating on Natera (NTRA) with a $310 price target, following the stock's close at $264.22. This follows a recent Buy from J.P. Morgan, while Goldman Sachs previously held a Hold rating. Burstein, known for strong performance in the healthcare sector, continues to view Natera favorably.
Bernstein analyst Eve Burstein maintained a Buy rating on Natera yesterday and set a price target of $310.00. The company’s shares closed yesterday at $264.22.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Burstein covers the Healthcare sector, focusing on stocks such as Natera, Guardant Health, and Agilent. According to TipRanks, Burstein has an average return of 27.0% and a 70.00% success rate on recommended stocks.
In addition to Bernstein, Natera also received a Buy from J.P. Morgan’s Casey Woodring in a report issued on July 21. However, on July 14, Goldman Sachs maintained a Hold rating on Natera (NASDAQ: NTRA).